Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
o2h Ventures is a venture capital firm based in Cambridge, UK, specializing in the biotechnology sector. Founded to support early-stage biotech companies, o2h Ventures focuses on seeding innovative therapeutics and artificial intelligence opportunities. The firm operates under the Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS) frameworks, which enable it to invest in promising startups developing novel drug discovery tools and technologies.
As of now, o2h Ventures manages assets totaling approximately £1.1 million, with a target fund size of £10 million for both its EIS and SEIS funds. The firm operates from the Mill SciTech Park in Hauxton, providing a conducive environment for life-science startups. The team comprises experienced professionals with backgrounds in life sciences, technology, and entrepreneurship, allowing them to offer significant support to portfolio companies.
o2h Ventures primarily invests in early-stage companies within the biotechnology sector, particularly those focused on novel drug discovery and enabling services, tools, and AI technologies. The firm seeks to support startups that are developing groundbreaking solutions in human health, leveraging its unique position within the Cambridge biotech ecosystem. Investment stages include pre-seed and seed, with a focus on companies eligible for SEIS and EIS funding.
The firm’s investment strategy emphasizes collaboration with startups that have strong scientific foundations and innovative ideas. o2h Ventures is particularly interested in sectors such as oncology, immuno-oncology, neuroscience, anti-infectives, and digital therapeutics. The firm aims to provide not only capital but also scientific support, strategic mentorship, and access to co-working lab and office space, ensuring that startups have the resources they need to succeed.
o2h Ventures has invested in six notable companies within the biotechnology sector:
Sunil Shah (Chief Executive Officer) — Sunil is a serial entrepreneur with a background in life sciences and technology. He began his career in PA Consulting’s Life Sciences team and co-founded Oxygen Healthcare, which was acquired by Piramal Enterprises. He co-founded o2h Ventures and is involved in drug-discovery seeding and biotech incubation.
Prashant Shah (Director) — Prashant is a serial entrepreneur with experience in strategy at Accenture. He co-founded several technology and life-sciences companies, including a drug-discovery firm acquired by a public company. He focuses on seeding and incubating early-stage life-science companies.
Andy Morley (Chief Scientific Officer) — Andy is a medicinal chemist with extensive experience in the pharmaceutical industry, providing scientific evaluation and portfolio input for o2h Ventures.
Gary Pitts (Compliance Consultant, Tetractys Limited) — Gary is a senior compliance professional and former regulator who supports o2h Ventures in maintaining regulatory standards.
To pitch to o2h Ventures, founders should send their proposals via email to invest@o2h.com. It is recommended to include a detailed deck that outlines the business model, scientific validation, and market opportunity. Founders can also download the prospectus from their website for more information on the funds.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions are preferred, especially from trusted contacts within the biotech community.
o2h human health EIS Knowledge Intensive Fund: This fund focuses on seeding early-stage biotech therapeutics and AI opportunities. It is recognized as Britain's first HMRC approved EIS knowledge intensive fund.
o2h human health SEIS Fund: This fund invests in seed-stage companies covering novel drug discovery and related enabling services, tools, and AI technologies.
In November 2025, o2h Ventures participated in a follow-on seed round for CamGene Therapeutics, which is developing RNA-based therapeutics for hearing loss. This investment highlights o2h's commitment to supporting innovative biotech solutions.
In February 2026, o2h Ventures was shortlisted for an award recognizing its contributions to the biotech sector, further establishing its reputation within the industry.
What are o2h Ventures' investment criteria?
o2h Ventures invests in early-stage biotech companies, particularly those involved in novel drug discovery and AI technologies. They focus on startups that are developing innovative solutions in human health.
How can I apply or pitch to o2h Ventures?
Founders can pitch to o2h Ventures by sending an email to invest@o2h.com. They also provide a prospectus available for download on their website.
What makes o2h Ventures different from other investors?
o2h Ventures differentiates itself through its deep connections within the biotech community, providing not only capital but also scientific support, strategic mentorship, and access to co-working lab space.
What is the geographic focus of o2h Ventures?
The firm primarily focuses on investments in the UK, especially within the Cambridge biotech ecosystem and university spinouts.
What are the typical check sizes for investments?
While specific portfolio company check sizes are not disclosed, the minimum investment amounts are £25,000 for the EIS fund and £10,000 for the SEIS fund.
What kind of post-investment involvement does o2h Ventures have?
o2h Ventures provides ongoing support to its portfolio companies through strategic mentorship, scientific guidance, and operational assistance, ensuring that startups can effectively navigate their growth stages.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.